Trehalose eye drops in the treatment of dry eye syndrome (Q44203592)

30 November 2017

title

Trehalose eye drops in the treatment of dry eye syndrome (English)

1 reference

30 November 2017

main subject

alpha,alpha-trehalose

1 reference

Toshihiko Matsuo

1

1 reference

30 November 2017

Yozo Tsuchida

series ordinal

2

1 reference

30 November 2017

Noriko Morimoto

series ordinal

3

1 reference

30 November 2017

publication date

1 November 2002

1 reference

30 November 2017

1 reference

30 November 2017

volume

109

1 reference

30 November 2017

issue

11

1 reference

30 November 2017

page(s)

2024-2029

1 reference

Prevalence of dry eye among the elderly

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

The epidemiology of dry eye in Melbourne, Australia

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Prevalence of and risk factors for dry eye syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Three different types of dry eye syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Sodium hyaluronate eyedrops in the treatment of dry eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Efficacy and safety of 0.3% carbomer gel compared to placebo in patients with moderate-to-severe dry eye syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

1 reference

7 January 2021

The role of vitrification in anhydrobiosis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Trehalose expression confers desiccation tolerance on human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Trehalose protects corneal epithelial cells from death by drying

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Diagnostic tests in the Sicca syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Studien zur Physiologie und Pathologie der Tränenabsonderung und Tränenabfuhr

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Factors Affecting Tear Film Breakup in Normal Eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Sjögren's syndrome. Proposed criteria for classification

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

Ocular fatigue is the major symptom of dry eye

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2802%2901219-8

7 January 2021

10.1016/S0161-6420(02)01219-8

Identifiers

DOI

1 reference

30 November 2017

1 reference